Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Food and Drug Administration (FDA), the most common co-covered peer. Coverage clusters in pharma, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 3 original sources each.
2 verified stories tracked
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Food and Drug Administration (FDA), the most common co-covered peer. Coverage clusters in pharma, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 3 original sources each. American Medical Association (AMA) appears in 2 tracked Cross-Sector stories from March 9, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering American Medical Association (AMA). Shared-story counts are live from our verified record — not editorial picks.
The pharmaceutical industry faces renewed scrutiny over direct-to-consumer (DTC) advertising, a practice unique to the U.S. and New Zealand. As healthcare costs rise, regulators are weighing the educational benefits of these ads against their role in driving up prescription volumes and drug prices.
A renewed public debate over Direct-to-Consumer Advertising (DTCA) is challenging the pharmaceutical industry's marketing status quo in the United States. As healthcare costs escalate, regulators and lawmakers are weighing the educational benefits of patient outreach against the risks of over-prescription and inflated drug prices.
